JP2013503875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503875A5 JP2013503875A5 JP2012527985A JP2012527985A JP2013503875A5 JP 2013503875 A5 JP2013503875 A5 JP 2013503875A5 JP 2012527985 A JP2012527985 A JP 2012527985A JP 2012527985 A JP2012527985 A JP 2012527985A JP 2013503875 A5 JP2013503875 A5 JP 2013503875A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- heteroaryl
- conr
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 902
- 125000000623 heterocyclic group Chemical group 0.000 claims 704
- 125000001072 heteroaryl group Chemical group 0.000 claims 701
- 125000003118 aryl group Chemical group 0.000 claims 461
- 125000003342 alkenyl group Chemical group 0.000 claims 383
- 125000003545 alkoxy group Chemical group 0.000 claims 375
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 255
- 229910052757 nitrogen Inorganic materials 0.000 claims 253
- 229910052717 sulfur Inorganic materials 0.000 claims 252
- 125000005842 heteroatom Chemical group 0.000 claims 251
- 229910052760 oxygen Inorganic materials 0.000 claims 248
- 229910052799 carbon Inorganic materials 0.000 claims 238
- 125000004432 carbon atom Chemical group C* 0.000 claims 237
- 125000005843 halogen group Chemical group 0.000 claims 233
- 229910052794 bromium Inorganic materials 0.000 claims 231
- 229910052740 iodine Inorganic materials 0.000 claims 231
- 229910052801 chlorine Inorganic materials 0.000 claims 225
- 125000000753 cycloalkyl group Chemical group 0.000 claims 206
- 125000004093 cyano group Chemical group *C#N 0.000 claims 203
- 125000000304 alkynyl group Chemical group 0.000 claims 138
- 229910052739 hydrogen Inorganic materials 0.000 claims 65
- 239000003814 drug Substances 0.000 claims 49
- 229940079593 drug Drugs 0.000 claims 42
- 239000003795 chemical substances by application Substances 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 24
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000003146 anticoagulant agent Substances 0.000 claims 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 125000004122 cyclic group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 12
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 10
- 125000004429 atom Chemical group 0.000 claims 10
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 7
- 229940083712 aldosterone antagonist Drugs 0.000 claims 7
- 229940127003 anti-diabetic drug Drugs 0.000 claims 7
- 239000000883 anti-obesity agent Substances 0.000 claims 7
- 229940124605 anti-osteoporosis drug Drugs 0.000 claims 7
- 230000001028 anti-proliverative effect Effects 0.000 claims 7
- 230000002785 anti-thrombosis Effects 0.000 claims 7
- 230000000767 anti-ulcer Effects 0.000 claims 7
- 239000003416 antiarrhythmic agent Substances 0.000 claims 7
- 229940127219 anticoagulant drug Drugs 0.000 claims 7
- 239000000935 antidepressant agent Substances 0.000 claims 7
- 229940005513 antidepressants Drugs 0.000 claims 7
- 229940127088 antihypertensive drug Drugs 0.000 claims 7
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 229940041181 antineoplastic drug Drugs 0.000 claims 7
- 229940127218 antiplatelet drug Drugs 0.000 claims 7
- 239000003420 antiserotonin agent Substances 0.000 claims 7
- 239000002249 anxiolytic agent Substances 0.000 claims 7
- 230000000949 anxiolytic effect Effects 0.000 claims 7
- 229940005530 anxiolytics Drugs 0.000 claims 7
- 229940097217 cardiac glycoside Drugs 0.000 claims 7
- 239000002368 cardiac glycoside Substances 0.000 claims 7
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 7
- 235000012000 cholesterol Nutrition 0.000 claims 7
- 239000002934 diuretic Substances 0.000 claims 7
- 229940030606 diuretics Drugs 0.000 claims 7
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 claims 7
- 229960002084 dronedarone Drugs 0.000 claims 7
- 239000003527 fibrinolytic agent Substances 0.000 claims 7
- 239000003324 growth hormone secretagogue Substances 0.000 claims 7
- 238000002657 hormone replacement therapy Methods 0.000 claims 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 7
- 150000002632 lipids Chemical class 0.000 claims 7
- 239000002394 mineralocorticoid antagonist Substances 0.000 claims 7
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 7
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 7
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 7
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 7
- 229930002534 steroid glycoside Natural products 0.000 claims 7
- 150000008143 steroidal glycosides Chemical class 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 210000001685 thyroid gland Anatomy 0.000 claims 7
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 7
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 5
- 239000003472 antidiabetic agent Substances 0.000 claims 5
- 239000002220 antihypertensive agent Substances 0.000 claims 5
- 239000000480 calcium channel blocker Substances 0.000 claims 5
- -1 (4-aminopiperidinyl) sulfonyl Chemical group 0.000 claims 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 206010003119 arrhythmia Diseases 0.000 claims 4
- 230000006793 arrhythmia Effects 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 229940127234 oral contraceptive Drugs 0.000 claims 4
- 239000003539 oral contraceptive agent Substances 0.000 claims 4
- 230000003637 steroidlike Effects 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 108090000312 Calcium Channels Proteins 0.000 claims 2
- 102000003922 Calcium Channels Human genes 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 208000000689 peptic esophagitis Diseases 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- WNKYTCDVQGQNGF-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[3-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]-1,2,4-oxadiazol-5-yl]methanone Chemical compound C1CC(N)CCN1C(=O)C1=NC(C=2C=C(C=NC=2)C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=NO1 WNKYTCDVQGQNGF-UHFFFAOYSA-N 0.000 claims 1
- KCMPNIHDCHNBLR-UHFFFAOYSA-N 1-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]-4,5-dihydro-1,2-oxazol-3-yl]butan-1-one Chemical compound C1C(C(=O)CCC)=NOC1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 KCMPNIHDCHNBLR-UHFFFAOYSA-N 0.000 claims 1
- CFIPTVYHUSQTPE-UHFFFAOYSA-N 1-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]cyclopropane-1-carbonitrile Chemical compound C=1N=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=CC=1C1(C#N)CC1 CFIPTVYHUSQTPE-UHFFFAOYSA-N 0.000 claims 1
- YFHBVPJJSPKCBC-UHFFFAOYSA-N 1-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]ethanol Chemical compound CC(O)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 YFHBVPJJSPKCBC-UHFFFAOYSA-N 0.000 claims 1
- WRQMKFLJGNZAMX-UHFFFAOYSA-N 1-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]cyclopropane-1-carbonitrile Chemical compound N=1C(NCC=2N=CC=CC=2)=C2C(C=3C=CC=CC=3)=CC=CC2=NC=1C1(C#N)CC1 WRQMKFLJGNZAMX-UHFFFAOYSA-N 0.000 claims 1
- BJMGXMYXAHQFBO-UHFFFAOYSA-N 1-methyl-2-oxo-5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide Chemical compound C1=C(S(N)(=O)=O)C(=O)N(C)C=C1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 BJMGXMYXAHQFBO-UHFFFAOYSA-N 0.000 claims 1
- RAEQCNSUDIRZQO-UHFFFAOYSA-N 2-(2-aminopyrimidin-5-yl)-5-phenyl-n-(pyridin-2-ylmethyl)quinazolin-4-amine Chemical compound C1=NC(N)=NC=C1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 RAEQCNSUDIRZQO-UHFFFAOYSA-N 0.000 claims 1
- VBVACLJOGCQGTG-UHFFFAOYSA-N 2-(2-methoxypyrimidin-5-yl)-5-phenyl-n-(pyridin-2-ylmethyl)quinazolin-4-amine Chemical compound C1=NC(OC)=NC=C1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 VBVACLJOGCQGTG-UHFFFAOYSA-N 0.000 claims 1
- QHIYHJYIEGGUOX-UHFFFAOYSA-N 2-(5-aminopyridin-3-yl)-5-phenyl-n-(pyridin-2-ylmethyl)quinazolin-4-amine Chemical compound NC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 QHIYHJYIEGGUOX-UHFFFAOYSA-N 0.000 claims 1
- XYSIEZSDRWTZEA-UHFFFAOYSA-N 2-[5-(1,2,4-oxadiazol-3-yl)pyridin-3-yl]-5-phenyl-n-(pyridin-2-ylmethyl)quinazolin-4-amine Chemical compound C=1C=CC=NC=1CNC(C=12)=NC(C=3C=C(C=NC=3)C3=NOC=N3)=NC2=CC=CC=1C1=CC=CC=C1 XYSIEZSDRWTZEA-UHFFFAOYSA-N 0.000 claims 1
- ZEETZZJMRKEACQ-UHFFFAOYSA-N 2-[5-(1,3,4-oxadiazol-2-yl)pyridin-3-yl]-5-phenyl-n-(pyridin-2-ylmethyl)quinazolin-4-amine Chemical compound C=1C=CC=NC=1CNC(C=12)=NC(C=3C=C(C=NC=3)C=3OC=NN=3)=NC2=CC=CC=1C1=CC=CC=C1 ZEETZZJMRKEACQ-UHFFFAOYSA-N 0.000 claims 1
- CKHRJXSBXGIPIU-UHFFFAOYSA-N 2-[5-(3,5-dimethyl-1,2-oxazol-4-yl)pyridin-3-yl]-5-phenyl-n-(pyridin-2-ylmethyl)quinazolin-4-amine Chemical compound CC1=NOC(C)=C1C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 CKHRJXSBXGIPIU-UHFFFAOYSA-N 0.000 claims 1
- IZKJBTRAWREWFD-UHFFFAOYSA-N 2-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]acetamide Chemical compound NC(=O)CC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 IZKJBTRAWREWFD-UHFFFAOYSA-N 0.000 claims 1
- FVMLHPCDJCQAPK-UHFFFAOYSA-N 2-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]acetonitrile Chemical compound N#CCC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 FVMLHPCDJCQAPK-UHFFFAOYSA-N 0.000 claims 1
- DCZRNAOHORCJCS-UHFFFAOYSA-N 2-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]ethanesulfonamide Chemical compound NS(=O)(=O)CCC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 DCZRNAOHORCJCS-UHFFFAOYSA-N 0.000 claims 1
- ORAPDKIAZMXQNT-UHFFFAOYSA-N 2-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]propan-2-ol Chemical compound CC(C)(O)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 ORAPDKIAZMXQNT-UHFFFAOYSA-N 0.000 claims 1
- VPKRECDQVAXWPK-UHFFFAOYSA-N 2-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]propanamide Chemical compound NC(=O)C(C)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 VPKRECDQVAXWPK-UHFFFAOYSA-N 0.000 claims 1
- CSRQWQAFGUGBMQ-UHFFFAOYSA-N 2-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]propane-1,3-diol Chemical compound OCC(CO)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 CSRQWQAFGUGBMQ-UHFFFAOYSA-N 0.000 claims 1
- PDIQUSOLRPLOGI-UHFFFAOYSA-N 2-[[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]methylsulfonyl]acetamide Chemical compound NC(=O)CS(=O)(=O)CC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 PDIQUSOLRPLOGI-UHFFFAOYSA-N 0.000 claims 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 claims 1
- SDKFQIYNQXUBFN-UHFFFAOYSA-N 2-amino-5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide Chemical compound C1=C(S(N)(=O)=O)C(N)=NC=C1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 SDKFQIYNQXUBFN-UHFFFAOYSA-N 0.000 claims 1
- HJAQLGANXHYRSF-UHFFFAOYSA-N 2-chloro-5-phenyl-n-pyridin-2-ylquinazolin-4-amine Chemical compound C=12C(C=3C=CC=CC=3)=CC=CC2=NC(Cl)=NC=1NC1=CC=CC=N1 HJAQLGANXHYRSF-UHFFFAOYSA-N 0.000 claims 1
- YCHLARAVEDTNCP-UHFFFAOYSA-N 2-cyclopropyl-5-phenyl-n-(pyridin-2-ylmethyl)quinazolin-4-amine Chemical compound C=1C=CC=NC=1CNC(C=12)=NC(C3CC3)=NC2=CC=CC=1C1=CC=CC=C1 YCHLARAVEDTNCP-UHFFFAOYSA-N 0.000 claims 1
- ADPOMRGQHUPZED-UHFFFAOYSA-N 2-methoxy-5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide Chemical compound C1=C(S(N)(=O)=O)C(OC)=NC=C1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 ADPOMRGQHUPZED-UHFFFAOYSA-N 0.000 claims 1
- AIWGUQUXNSMXNH-UHFFFAOYSA-N 2-methyl-1-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]propan-1-ol Chemical compound CC(C)C(O)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 AIWGUQUXNSMXNH-UHFFFAOYSA-N 0.000 claims 1
- DQDWIXDURRTWQQ-UHFFFAOYSA-N 2-methyl-2-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]propanenitrile Chemical compound N#CC(C)(C)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 DQDWIXDURRTWQQ-UHFFFAOYSA-N 0.000 claims 1
- VKGUZDMOYVPPLI-UHFFFAOYSA-N 2-methyl-2-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]propane-1,3-diol Chemical compound C=12C(C=3C=CC=CC=3)=CC=CC2=NC(C(CO)(CO)C)=NC=1NCC1=CC=CC=N1 VKGUZDMOYVPPLI-UHFFFAOYSA-N 0.000 claims 1
- KGBPICWXCWNDSD-UHFFFAOYSA-N 2-methyl-6-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]imidazo[1,2-a]pyridine-8-sulfonamide Chemical compound C1=C(S(N)(=O)=O)C2=NC(C)=CN2C=C1C(N=C1C=CC=C(C1=1)C=2C=CC=CC=2)=NC=1NCC1=CC=CC=N1 KGBPICWXCWNDSD-UHFFFAOYSA-N 0.000 claims 1
- ZDRPFFAIGWCFRK-UHFFFAOYSA-N 3-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]-1,2,4-oxadiazole-5-carboxamide Chemical compound O1C(C(=O)N)=NC(C=2C=C(C=NC=2)C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=N1 ZDRPFFAIGWCFRK-UHFFFAOYSA-N 0.000 claims 1
- CRBPVOYQPCSBGD-UHFFFAOYSA-N 3-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]propanamide Chemical compound NC(=O)CCC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 CRBPVOYQPCSBGD-UHFFFAOYSA-N 0.000 claims 1
- WNSUHLRXJPCQQL-UHFFFAOYSA-N 4-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 WNSUHLRXJPCQQL-UHFFFAOYSA-N 0.000 claims 1
- JJQNGYRROPWYJT-UHFFFAOYSA-N 4-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]but-3-yn-1-ol Chemical compound C=12C(C=3C=CC=CC=3)=CC=CC2=NC(C#CCCO)=NC=1NCC1=CC=CC=N1 JJQNGYRROPWYJT-UHFFFAOYSA-N 0.000 claims 1
- XPJNIZBBYJXAEK-UHFFFAOYSA-N 4-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]piperidine-1-sulfonamide Chemical compound C1CN(S(=O)(=O)N)CCC1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 XPJNIZBBYJXAEK-UHFFFAOYSA-N 0.000 claims 1
- MJJFPHTURAZWKX-UHFFFAOYSA-N 5-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]-1,3,4-oxadiazol-2-amine Chemical compound O1C(N)=NN=C1C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 MJJFPHTURAZWKX-UHFFFAOYSA-N 0.000 claims 1
- DTWBCZCMEULUNG-UHFFFAOYSA-N 5-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]-1,3,4-oxadiazole-2-carboxamide Chemical compound O1C(C(=O)N)=NN=C1C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 DTWBCZCMEULUNG-UHFFFAOYSA-N 0.000 claims 1
- KITYXUGKWPDMSJ-UHFFFAOYSA-N 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]-1h-pyridin-2-one Chemical compound N1C(=O)C=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 KITYXUGKWPDMSJ-UHFFFAOYSA-N 0.000 claims 1
- XGKULQQVQWCASY-UHFFFAOYSA-N 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 XGKULQQVQWCASY-UHFFFAOYSA-N 0.000 claims 1
- HEDAUIXNFZMILW-UHFFFAOYSA-N 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyrimidine-2-carbonitrile Chemical compound C1=NC(C#N)=NC=C1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 HEDAUIXNFZMILW-UHFFFAOYSA-N 0.000 claims 1
- GYEMDCYWSZCBGX-UHFFFAOYSA-N 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyrimidine-2-carboxamide Chemical compound C1=NC(C(=O)N)=NC=C1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 GYEMDCYWSZCBGX-UHFFFAOYSA-N 0.000 claims 1
- QPZKONBYBJXIFG-UHFFFAOYSA-N 5-phenyl-4-(pyridin-2-ylmethylamino)-2-[1-[(sulfamoylamino)methyl]cyclopropyl]quinazoline Chemical compound N=1C(NCC=2N=CC=CC=2)=C2C(C=3C=CC=CC=3)=CC=CC2=NC=1C1(CNS(=O)(=O)N)CC1 QPZKONBYBJXIFG-UHFFFAOYSA-N 0.000 claims 1
- GPYUSYNKDNQBNE-UHFFFAOYSA-N 5-phenyl-4-(pyridin-2-ylmethylamino)-2-[5-(sulfamoylamino)pyridin-3-yl]quinazoline Chemical compound NS(=O)(=O)NC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 GPYUSYNKDNQBNE-UHFFFAOYSA-N 0.000 claims 1
- VZKHWWWTMNZHEU-UHFFFAOYSA-N 5-phenyl-N-(pyridin-2-ylmethyl)-2-pyrimidin-5-ylquinazolin-4-amine 5-phenyl-2-pyrimidin-5-yl-3H-quinazolin-4-one Chemical compound O=c1[nH]c(nc2cccc(-c3ccccc3)c12)-c1cncnc1.C(Nc1nc(nc2cccc(-c3ccccc3)c12)-c1cncnc1)c1ccccn1 VZKHWWWTMNZHEU-UHFFFAOYSA-N 0.000 claims 1
- UHUXOLGACMTMER-UHFFFAOYSA-N 5-phenyl-n-(pyridin-2-ylmethyl)-2-(2,2,5-trimethyl-1,3-dioxan-5-yl)quinazolin-4-amine Chemical compound C1OC(C)(C)OCC1(C)C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 UHUXOLGACMTMER-UHFFFAOYSA-N 0.000 claims 1
- ZMTTVRRCZREMLV-UHFFFAOYSA-N 5-phenyl-n-(pyridin-2-ylmethyl)-2-(2h-triazol-4-yl)quinazolin-4-amine Chemical compound C=1C=CC=NC=1CNC(C=12)=NC(C3=NNN=C3)=NC2=CC=CC=1C1=CC=CC=C1 ZMTTVRRCZREMLV-UHFFFAOYSA-N 0.000 claims 1
- DCKQCZSGFVXJQD-UHFFFAOYSA-N 5-phenyl-n-(pyridin-2-ylmethyl)-2-(trifluoromethyl)quinazolin-4-amine Chemical compound C=12C(C=3C=CC=CC=3)=CC=CC2=NC(C(F)(F)F)=NC=1NCC1=CC=CC=N1 DCKQCZSGFVXJQD-UHFFFAOYSA-N 0.000 claims 1
- OVNREXDNGOVHCG-UHFFFAOYSA-N 5-phenyl-n-(pyridin-2-ylmethyl)-2-[5-(1,2,4-triazol-4-yl)pyridin-3-yl]quinazolin-4-amine Chemical compound C=1C=CC=NC=1CNC(C=12)=NC(C=3C=C(C=NC=3)N3C=NN=C3)=NC2=CC=CC=1C1=CC=CC=C1 OVNREXDNGOVHCG-UHFFFAOYSA-N 0.000 claims 1
- ULDPBZLCZOEGTF-UHFFFAOYSA-N 5-phenyl-n-(pyridin-2-ylmethyl)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]quinazolin-4-amine Chemical compound O1C(C(F)(F)F)=NC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=N1 ULDPBZLCZOEGTF-UHFFFAOYSA-N 0.000 claims 1
- VQGXMSITFWZMRF-UHFFFAOYSA-N 6-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound C=1N=C2NC(=O)NC2=CC=1C(N=C1C=CC=C(C1=1)C=2C=CC=CC=2)=NC=1NCC1=CC=CC=N1 VQGXMSITFWZMRF-UHFFFAOYSA-N 0.000 claims 1
- MUQYRIDVHPKYKS-UHFFFAOYSA-N 6-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyrazine-2-sulfonamide Chemical compound NS(=O)(=O)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=N1 MUQYRIDVHPKYKS-UHFFFAOYSA-N 0.000 claims 1
- 241000162682 Heterogen Species 0.000 claims 1
- AGBLAKRVOJGRKT-UHFFFAOYSA-N [5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]methanol Chemical compound OCC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 AGBLAKRVOJGRKT-UHFFFAOYSA-N 0.000 claims 1
- USSODORNBVBVFT-UHFFFAOYSA-N [5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]urea Chemical compound NC(=O)NC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 USSODORNBVBVFT-UHFFFAOYSA-N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- QYBPUCIBGMCKPB-UHFFFAOYSA-N methyl 3-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]-1,2,4-oxadiazole-5-carboxylate Chemical compound O1C(C(=O)OC)=NC(C=2C=C(C=NC=2)C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=N1 QYBPUCIBGMCKPB-UHFFFAOYSA-N 0.000 claims 1
- BKTVVVVSDQVHEI-UHFFFAOYSA-N methyl 3-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]propanoate Chemical compound COC(=O)CCC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 BKTVVVVSDQVHEI-UHFFFAOYSA-N 0.000 claims 1
- NSQNJIOTYOYVPJ-UHFFFAOYSA-N methyl 5-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]-1,3,4-oxadiazole-2-carboxylate Chemical compound O1C(C(=O)OC)=NN=C1C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 NSQNJIOTYOYVPJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- FZILBCDDESQHAI-UHFFFAOYSA-N n-(2-methoxyethyl)-5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide Chemical compound COCCNS(=O)(=O)C1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 FZILBCDDESQHAI-UHFFFAOYSA-N 0.000 claims 1
- LRVVBPZHOLIFKZ-UHFFFAOYSA-N n-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]acetamide Chemical compound CC(=O)NC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 LRVVBPZHOLIFKZ-UHFFFAOYSA-N 0.000 claims 1
- SHRUFOHFMSBOSJ-UHFFFAOYSA-N n-[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 SHRUFOHFMSBOSJ-UHFFFAOYSA-N 0.000 claims 1
- JQUHYGFWCNJOLE-UHFFFAOYSA-N n-[[1-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]cyclopropyl]methyl]methanesulfonamide Chemical compound N=1C(NCC=2N=CC=CC=2)=C2C(C=3C=CC=CC=3)=CC=CC2=NC=1C1(CNS(=O)(=O)C)CC1 JQUHYGFWCNJOLE-UHFFFAOYSA-N 0.000 claims 1
- JPVHKVBAXFJQFG-UHFFFAOYSA-N n-[[5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridin-3-yl]methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1=CN=CC(C=2N=C3C=CC=C(C3=C(NCC=3N=CC=CC=3)N=2)C=2C=CC=CC=2)=C1 JPVHKVBAXFJQFG-UHFFFAOYSA-N 0.000 claims 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 claims 1
- PRWJCIOUDJPBJR-UHFFFAOYSA-N tert-butyl 4-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NC(NCC=2N=CC=CC=2)=C(C(=CC=C2)C=3C=CC=CC=3)C2=N1 PRWJCIOUDJPBJR-UHFFFAOYSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 0 C*(c1cccc(-c(cc2)c(*)c(C)c2N)c1C(*(*)*)=*)=C(*)* Chemical compound C*(c1cccc(-c(cc2)c(*)c(C)c2N)c1C(*(*)*)=*)=C(*)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23945209P | 2009-09-03 | 2009-09-03 | |
| US61/239,452 | 2009-09-03 | ||
| PCT/US2010/047430 WO2011028741A1 (en) | 2009-09-03 | 2010-09-01 | Quinazolines as potassium ion channel inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014221908A Division JP5950978B2 (ja) | 2009-09-03 | 2014-10-30 | カリウムイオンチャネルインヒビターとしてのキナゾリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013503875A JP2013503875A (ja) | 2013-02-04 |
| JP2013503875A5 true JP2013503875A5 (https=) | 2013-04-25 |
| JP5643312B2 JP5643312B2 (ja) | 2014-12-17 |
Family
ID=42942118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527985A Active JP5643312B2 (ja) | 2009-09-03 | 2010-09-01 | カリウムイオンチャネルインヒビターとしてのキナゾリン |
| JP2014221908A Active JP5950978B2 (ja) | 2009-09-03 | 2014-10-30 | カリウムイオンチャネルインヒビターとしてのキナゾリン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014221908A Active JP5950978B2 (ja) | 2009-09-03 | 2014-10-30 | カリウムイオンチャネルインヒビターとしてのキナゾリン |
Country Status (32)
| Country | Link |
|---|---|
| US (9) | US8575184B2 (https=) |
| EP (3) | EP3575288B1 (https=) |
| JP (2) | JP5643312B2 (https=) |
| KR (1) | KR101698631B1 (https=) |
| CN (1) | CN102753535B (https=) |
| AR (1) | AR078326A1 (https=) |
| AU (1) | AU2010289641B2 (https=) |
| BR (1) | BR112012008330B1 (https=) |
| CA (1) | CA2772642C (https=) |
| CL (1) | CL2012000583A1 (https=) |
| CO (1) | CO6511220A2 (https=) |
| CY (2) | CY1118488T1 (https=) |
| DK (2) | DK2473487T3 (https=) |
| EA (1) | EA021113B1 (https=) |
| ES (3) | ES2750598T3 (https=) |
| HR (2) | HRP20211973T1 (https=) |
| HU (2) | HUE032983T2 (https=) |
| IL (1) | IL218169A (https=) |
| LT (2) | LT3575288T (https=) |
| MX (1) | MX2012002099A (https=) |
| MY (1) | MY160243A (https=) |
| NZ (1) | NZ598516A (https=) |
| PE (1) | PE20121153A1 (https=) |
| PL (2) | PL3575288T3 (https=) |
| PT (2) | PT3575288T (https=) |
| SG (1) | SG178592A1 (https=) |
| SI (2) | SI3575288T1 (https=) |
| SM (3) | SMT201700026T1 (https=) |
| TN (1) | TN2012000063A1 (https=) |
| TW (1) | TWI488851B (https=) |
| WO (1) | WO2011028741A1 (https=) |
| ZA (1) | ZA201202383B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH068949B2 (ja) | 1985-09-20 | 1994-02-02 | 富士写真フイルム株式会社 | ハロゲン化銀カラ−写真感光材料 |
| SMT201700026T1 (it) * | 2009-09-03 | 2017-03-08 | Bristol Myers Squibb Co | Chinazoline come inibitori dei canali degli ioni potassio |
| AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| KR20140048216A (ko) * | 2011-06-29 | 2014-04-23 | 오츠카 세이야쿠 가부시키가이샤 | 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법 |
| JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| CN103360382B (zh) * | 2012-03-26 | 2016-04-27 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及其用途 |
| SMT201800369T1 (it) * | 2012-06-11 | 2018-09-13 | Bristol Myers Squibb Co | Profarmaci di acido fosforamidico di 5-[5-fenil-4-piridin-2-il-metilammino)chinazolin-2-il}piridina-3-solfonammide |
| CA2902624C (en) | 2013-02-28 | 2021-05-18 | Takeda Pharmaceutical Company Limited | Method for producing sulfonyl chloride compound |
| US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
| EP2970294B1 (en) * | 2013-03-11 | 2016-12-28 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| JP6386527B2 (ja) * | 2013-03-11 | 2018-09-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カリウムイオンチャネル阻害剤としてのピロロピリダジン |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| EP2970199A1 (en) | 2013-03-11 | 2016-01-20 | Bristol-Myers Squibb Company | Isoquinolines as potassium ion channel inhibitors |
| BR112016008406B1 (pt) * | 2013-10-17 | 2021-02-23 | Sumitomo Chemical Company, Limited | composto de tetrazolinona e aplicação do mesmo |
| US10519112B2 (en) | 2014-06-10 | 2019-12-31 | Ube Industries, Ltd. | Method for producing heteroaromatic sulfonamide compound |
| CN106458904B (zh) | 2014-06-10 | 2021-12-03 | 宇部兴产株式会社 | N-取代磺酰胺化合物及其制造方法 |
| US10774072B2 (en) | 2014-06-10 | 2020-09-15 | Ube Industries, Ltd. | Crystal of N-substituted sulfonamide compound |
| US9873702B2 (en) * | 2014-12-05 | 2018-01-23 | Southern Research Institute | Heterocyclic compounds as biogenic amine transport modulators |
| US10087148B2 (en) | 2014-12-05 | 2018-10-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institute Of Health | Quinazolines as biogenic amine transport modulators |
| EP3307715A1 (en) * | 2015-06-10 | 2018-04-18 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives |
| CN114984003B (zh) | 2016-05-03 | 2024-08-27 | 拜耳制药股份公司 | 芳族磺酰胺衍生物 |
| CN106432067B (zh) * | 2016-09-18 | 2019-04-19 | 北京天弘天达医药科技有限公司 | 一种3-吡啶磺酰氯的绿色化学合成方法 |
| WO2019081573A1 (en) * | 2017-10-29 | 2019-05-02 | Bayer Aktiengesellschaft | AROMATIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF ISCHEMIC CEREBRAL ACCIDENTS |
| JP2021522181A (ja) * | 2018-04-20 | 2021-08-30 | バイエル・アクチエンゲゼルシヤフト | 殺有害生物剤としてのヘテロアリール−トリアゾール化合物及びヘテロアリール−テトラゾール化合物 |
| WO2020234103A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| EP4214204A1 (en) | 2020-09-18 | 2023-07-26 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| US20250289806A1 (en) * | 2022-04-28 | 2025-09-18 | University Of Miami | Compounds for proliferative disorders |
| EP4587439A1 (en) | 2022-09-16 | 2025-07-23 | Bayer Aktiengesellschaft | Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer |
| EP4602049A1 (en) | 2022-10-13 | 2025-08-20 | Bayer Aktiengesellschaft | Sos1 inhibitors |
| WO2025202022A1 (en) | 2024-03-27 | 2025-10-02 | Bayer Aktiengesellschaft | Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3843791A (en) | 1973-01-11 | 1974-10-22 | Pfizer | Method of killing insects with quinazolinones and quinazoline-thiones |
| EP0498722B1 (fr) | 1991-02-07 | 1997-07-30 | Roussel Uclaf | Dérivés bicycliques azotés, leur procédé de préparation, les intermédiaires obtenus, leur application comme médicaments et les compositions pharmaceutiques les renfermant |
| US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| JP2657760B2 (ja) | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | ４−アミノキナゾリン誘導体およびそれを含有する医薬品 |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| DE69425804T2 (de) | 1993-06-17 | 2001-02-08 | Otsuka Pharmaceutical Factory, Inc. | Phosphonsäurediesterderivate |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| JPH083144A (ja) | 1994-06-21 | 1996-01-09 | Chugai Pharmaceut Co Ltd | キナゾリン及びキノリン誘導体 |
| TW414798B (en) | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AU7692996A (en) * | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
| NZ325248A (en) | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| WO1998029397A1 (en) | 1996-12-27 | 1998-07-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyrimidine compounds and medicinal use thereof |
| JP4713698B2 (ja) | 1997-03-05 | 2011-06-29 | スージェン， インク． | 疎水性薬剤の処方 |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| US7709479B1 (en) | 1999-09-21 | 2010-05-04 | Astrazeneca | Quinazoline derivatives and their use as pharmaceuticals |
| IL148903A0 (en) * | 1999-09-30 | 2002-09-12 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles |
| US6605615B2 (en) | 2000-03-01 | 2003-08-12 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| WO2002024667A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gmbh | 4-amino-quinazolines |
| HUP0302429A3 (en) | 2000-09-20 | 2004-01-28 | Merck Patent Gmbh | 4-amino-quinazolines, process for producing them, pharmaceutical compositions containing them and their use |
| WO2002062767A1 (en) | 2001-02-07 | 2002-08-15 | Sumitomo Pharmaceuticals Company, Limited | Novel quinazoline derivatives |
| WO2002092579A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
| US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| AU2003258662A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| AU2003292435A1 (en) | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents |
| AU2003290279A1 (en) | 2002-12-23 | 2004-07-14 | Astrazeneca Ab | Quinazoline derivatives |
| WO2004069145A2 (en) | 2003-02-07 | 2004-08-19 | Dr. Reddy's Laboratories Ltd. | Anticancer compounds, process for their preparation and pharmaceutical compositions containing them |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| US7713983B2 (en) | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| ZA200507979B (en) * | 2003-03-03 | 2007-03-28 | Vertex Pharma Inc | Quinazolines useful as modulators of ion channels |
| JP2006522109A (ja) | 2003-03-31 | 2006-09-28 | 大正製薬株式会社 | 新規なキナゾリン誘導体及びそれらの使用に関連する治療方法 |
| PL1641803T6 (pl) | 2003-06-11 | 2011-04-29 | Xention Ltd | Pochodne tienopirymidyny jako inhibitory kanału potasowego |
| BRPI0411514A (pt) | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | antagonistas de receptor toll-like de molécula pequena |
| NZ544472A (en) | 2003-07-03 | 2009-04-30 | Myriad Genetics Inc | Compounds and therapeutical use thereof |
| CA2539476C (en) * | 2003-09-23 | 2011-04-19 | Merck & Co., Inc. | Quinazoline potassium channel inhibitors |
| BRPI0415683A (pt) | 2003-11-03 | 2006-12-19 | Warner Lambert Co | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
| US20070225308A1 (en) | 2004-03-15 | 2007-09-27 | Kyowa Hakko Kogyo Co.,Ltd. | 2-Amino Quinazoline Derivative |
| BRPI0511917A (pt) | 2004-06-10 | 2008-01-15 | Xention Discovery Ltd | composto ou sais farmaceuticamente aceitáveis do mesmo, processo para preparar um composto, composição farmacêutica, método para tratar ou prevenir um distúrbio que requer a inibição do canal de potássio, e, uso de um composto |
| US20060014705A1 (en) | 2004-06-30 | 2006-01-19 | Howitz Konrad T | Compositions and methods for selectively activating human sirtuins |
| CN101031551A (zh) | 2004-07-06 | 2007-09-05 | 安吉永生物制药公司 | 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂 |
| JP5173429B2 (ja) | 2004-12-09 | 2013-04-03 | ゼンション・リミテッド | 化合物 |
| JP2008526734A (ja) | 2004-12-31 | 2008-07-24 | エスケー ケミカルズ カンパニー リミテッド | 糖尿及び肥満治療予防に有効なキナゾリン誘導体 |
| MX2007010037A (es) | 2005-02-18 | 2008-02-15 | Novartis Vaccines & Diagnostic | Agentes antiangiogenicos con aldesleucina. |
| WO2006097441A1 (en) | 2005-03-14 | 2006-09-21 | Neurosearch A/S | Potassium channel modulating agents and their medical use |
| DE602006012815D1 (de) | 2005-03-23 | 2010-04-22 | Hoffmann La Roche | Acetylenylpyrazolopyrimidinderivate als mglur2-antagonsten |
| BRPI0609650A2 (pt) | 2005-03-25 | 2010-04-20 | Tibotec Pharm Ltd | inibidores heterobicìlicos de hvc |
| US20070066632A1 (en) | 2005-03-25 | 2007-03-22 | Scios, Inc. | Fused bicyclic inhibitors of TGFbeta |
| JP5079500B2 (ja) | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | ２−アミノキナゾリン誘導体 |
| US20070049559A1 (en) | 2005-06-28 | 2007-03-01 | Bruce Pfeffer | Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of Gelatinase A in ocular cells |
| GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
| US20090306102A1 (en) | 2005-12-20 | 2009-12-10 | Eriksen Birgitte L | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases |
| EP1968968A1 (en) | 2005-12-21 | 2008-09-17 | PainCeptor Pharma Corp. | Compositions and methods for modulating gated ion channels |
| DE102006012251A1 (de) | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20100016293A1 (en) | 2006-07-03 | 2010-01-21 | Rogier Adriaan Smits | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use |
| WO2008023357A1 (en) | 2006-08-22 | 2008-02-28 | Technion Research And Development Foundation Ltd. | Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr) |
| US20100173332A1 (en) | 2006-09-07 | 2010-07-08 | Auckland Uniservices Limited | Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds |
| WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| US8039505B2 (en) | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| WO2008150827A1 (en) | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| WO2009006141A2 (en) | 2007-07-05 | 2009-01-08 | Bausch & Lomb Incorporated | Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof |
| US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
| CN101575333B (zh) | 2008-05-09 | 2011-06-22 | 和记黄埔医药（上海）有限公司 | 一种喹唑啉衍生物及其医药用途 |
| WO2009143246A2 (en) | 2008-05-21 | 2009-11-26 | Genentech, Inc. | Arylsulfonamide compounds, compositions and methods of use |
| SMT201700026T1 (it) * | 2009-09-03 | 2017-03-08 | Bristol Myers Squibb Co | Chinazoline come inibitori dei canali degli ioni potassio |
| EP2473054B1 (en) | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
-
2010
- 2010-09-01 SM SM20170026T patent/SMT201700026T1/it unknown
- 2010-09-01 PT PT191861293T patent/PT3575288T/pt unknown
- 2010-09-01 NZ NZ598516A patent/NZ598516A/xx unknown
- 2010-09-01 EP EP19186129.3A patent/EP3575288B1/en active Active
- 2010-09-01 KR KR1020127008470A patent/KR101698631B1/ko active Active
- 2010-09-01 US US13/393,328 patent/US8575184B2/en active Active
- 2010-09-01 ES ES16180810T patent/ES2750598T3/es active Active
- 2010-09-01 HU HUE10754824A patent/HUE032983T2/en unknown
- 2010-09-01 LT LTEP19186129.3T patent/LT3575288T/lt unknown
- 2010-09-01 WO PCT/US2010/047430 patent/WO2011028741A1/en not_active Ceased
- 2010-09-01 DK DK10754824.0T patent/DK2473487T3/en active
- 2010-09-01 MY MYPI2012000987A patent/MY160243A/en unknown
- 2010-09-01 BR BR112012008330-9A patent/BR112012008330B1/pt active IP Right Grant
- 2010-09-01 PE PE2012000290A patent/PE20121153A1/es active IP Right Grant
- 2010-09-01 PT PT107548240T patent/PT2473487T/pt unknown
- 2010-09-01 EP EP16180810.0A patent/EP3124475B1/en active Active
- 2010-09-01 AU AU2010289641A patent/AU2010289641B2/en active Active
- 2010-09-01 PL PL19186129T patent/PL3575288T3/pl unknown
- 2010-09-01 SI SI201032099T patent/SI3575288T1/sl unknown
- 2010-09-01 ES ES19186129T patent/ES2900504T3/es active Active
- 2010-09-01 SM SM20210717T patent/SMT202100717T1/it unknown
- 2010-09-01 TW TW099129546A patent/TWI488851B/zh active
- 2010-09-01 DK DK19186129.3T patent/DK3575288T3/da active
- 2010-09-01 HR HRP20211973TT patent/HRP20211973T1/hr unknown
- 2010-09-01 EA EA201270378A patent/EA021113B1/ru not_active IP Right Cessation
- 2010-09-01 ES ES10754824.0T patent/ES2609335T3/es active Active
- 2010-09-01 LT LTEP10754824.0T patent/LT2473487T/lt unknown
- 2010-09-01 HR HRP20161669TT patent/HRP20161669T1/hr unknown
- 2010-09-01 SG SG2012013918A patent/SG178592A1/en unknown
- 2010-09-01 MX MX2012002099A patent/MX2012002099A/es active IP Right Grant
- 2010-09-01 EP EP10754824.0A patent/EP2473487B1/en active Active
- 2010-09-01 JP JP2012527985A patent/JP5643312B2/ja active Active
- 2010-09-01 PL PL10754824T patent/PL2473487T3/pl unknown
- 2010-09-01 HU HUE19186129A patent/HUE057433T2/hu unknown
- 2010-09-01 SI SI201031326T patent/SI2473487T1/sl unknown
- 2010-09-01 CN CN201080049632.7A patent/CN102753535B/zh active Active
- 2010-09-01 CA CA2772642A patent/CA2772642C/en active Active
- 2010-09-03 AR ARP100103247A patent/AR078326A1/es active IP Right Grant
-
2012
- 2012-02-10 TN TNP2012000063A patent/TN2012000063A1/en unknown
- 2012-02-16 IL IL218169A patent/IL218169A/en active IP Right Grant
- 2012-03-02 CL CL2012000583A patent/CL2012000583A1/es unknown
- 2012-03-07 CO CO12040232A patent/CO6511220A2/es active IP Right Grant
- 2012-04-02 ZA ZA2012/02383A patent/ZA201202383B/en unknown
-
2013
- 2013-09-27 US US14/038,814 patent/US9458114B2/en active Active
-
2014
- 2014-10-30 JP JP2014221908A patent/JP5950978B2/ja active Active
-
2016
- 2016-08-29 US US15/249,710 patent/US9822096B2/en active Active
-
2017
- 2017-01-16 SM SM201700026T patent/SMT201700026B/it unknown
- 2017-01-23 CY CY20171100095T patent/CY1118488T1/el unknown
- 2017-10-04 US US15/724,566 patent/US10214511B2/en active Active
-
2019
- 2019-01-09 US US16/243,400 patent/US10676460B2/en active Active
-
2020
- 2020-05-01 US US16/864,825 patent/US11008306B2/en active Active
-
2021
- 2021-04-15 US US17/231,088 patent/US20220324836A1/en not_active Abandoned
- 2021-12-16 CY CY20211101107T patent/CY1125021T1/el unknown
-
2023
- 2023-03-24 US US18/125,826 patent/US20230322726A1/en not_active Abandoned
-
2025
- 2025-04-07 US US19/171,423 patent/US20250230144A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503875A5 (https=) | ||
| JP5950978B2 (ja) | カリウムイオンチャネルインヒビターとしてのキナゾリン | |
| JP5539734B2 (ja) | チオピリミジンベースの化合物およびその使用 | |
| KR102007056B1 (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
| KR101501785B1 (ko) | 과증식성 장애 및 혈관형성과 관련된 질환 치료에 유용한 치환된 2,3-디히드로이미다조［1,2-ｃ］퀴나졸린 유도체 | |
| JP5756518B2 (ja) | 複素環アルキニルベンゼン化合物と、その医療用組成物および使用 | |
| ES2873949T3 (es) | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona | |
| HRP20180413T1 (hr) | Inhibitori kinaza koji reguliraju signalne puteve u apoptozi | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| JP2012515787A5 (https=) | ||
| BR112021008905A2 (pt) | compostos de piridazinona e usos dos mesmos | |
| JP2019504009A5 (https=) | ||
| TWI455715B (zh) | ４－（４－氰基－２－硫基芳基）二氫嘧啶酮類及其用途 | |
| RS20060012A (sr) | Derivati trisupstituisanog arila i heteroarila kao modulatori metabolizma, u profilaksi i tretmanu sa njim povezanih oboljenja | |
| TW200536851A (en) | Compounds and methods of use | |
| CA2624602A1 (en) | Process for preparing 6-substituted-7-azaindoles | |
| EP2063897A2 (en) | Kinase inhibitors useful for the treatment of proliferative diseases | |
| BRPI0720270A2 (pt) | Compostos basedos em 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina e processos de usos dos mesmos | |
| JP2014525444A5 (https=) | ||
| WO2012087938A1 (en) | Quinazolinone derivatives as antiviral agents | |
| JP2011503230A5 (https=) | ||
| JP2006507247A5 (https=) | ||
| EP1424336A1 (en) | 1,3-benzothiazinone derivatives and use thereof | |
| RU2015128025A (ru) | Ингибиторы сомт | |
| JP2012522748A5 (https=) |